Trial · NCT00025233

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

NCT00025233, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2015-06-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix. Trials, record NCT00025233. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00025233

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
NCT number: NCT00025233
Status: Completed
Phases: Phase 2
Enrollment: 50 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Interventions: bevacizumab, laboratory biomarker analysis
First posted: 2003-01-27
Last updated: 2019-07-24
Results first posted: 2015-06-29

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-free Survival Greater Than 6 Months	Every other 3-week treatment cycle for 6 months	Whether or not the patient survived progression-free for at least 6 months.
Primary	Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Every cycle and 30 days after the end of treatment. (average 5 months)	The maximum severity of each adverse event per patient, graded according to Common Toxicity Criteria version 2.0, is reported. Events were restricted to those reported as at least possibly related to study drug.
Secondary	Tumor Response	Every other cycle during treatment and at the time of treatment discontinuation. (average 5 months)	RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate.
Secondary	Overall Survival	From study entry to death or last contact, up to 5 years.	The observed length of life from entry into the study to death or the date of last contact.
Secondary	Duration of Progression-free Survival	Every other cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years	Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.
Secondary	Performance Status	Baseline	Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
Secondary	Age at Enrollment	Baseline

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression-free Survival Greater Than 6 Months	Every other 3-week treatment cycle for 6 months	Eligible and Treated Patients	percentage of participants	NUMBER
PRIMARY	Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Every cycle and 30 days after the end of treatment. (average 5 months)	Eligible and treated patients	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Tumor Response	Every other cycle during treatment and at the time of treatment discontinuation. (average 5 months)	Eligible and treated patients.	percentage of participants	NUMBER
SECONDARY	Overall Survival	From study entry to death or last contact, up to 5 years.	Eligible and treated patients.	months	MEDIAN
SECONDARY	Duration of Progression-free Survival	Every other cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years	Eligible and treated patients	months	MEDIAN
SECONDARY	Performance Status	Baseline	Eligible and treated patients.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Age at Enrollment	Baseline	Eligible and treated patients	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group144

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression-free Survival Greater Than 6 Months	Bevacizumab		23.9	90% Confidence Interval 14.0 to 36.5	percentage of participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 0	Leukopenia	39		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 1 (CTCAE v 2.0)	Leukopenia	3		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 2 (CTCAE v 2.0)	Leukopenia	3		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 3 (CTCAE v 2.0)	Leukopenia	1		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 4 (CTCAE v 2.0)	Leukopenia	0		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 5 (CTCAE v 2.0)	Leukopenia	0		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 0	Thrombocytopenia	43		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 1 (CTCAE v 2.0)	Thrombocytopenia	3		Participants
Maximum Severity of Each Adverse Event Per Patient, Graded According to Common Toxicity Criteria Version 2.0	Grade 2 (CTCAE v 2.0)	Thrombocytopenia	0		Participants

1 to 10 of 144Source ClinicalTrials.gov

See all 144 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Bevacizumab	50
Overall Study	COMPLETED	Bevacizumab	46
Overall Study	NOT COMPLETED	Bevacizumab	4

Source ClinicalTrials.gov

Adverse events150

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Allergic Rhinitis	Immune system disorders	Bevacizumab	5	46
other	Allergic Reaction	Immune system disorders	Bevacizumab	1	46
other	Inner Ear/Hearing	Ear and labyrinth disorders	Bevacizumab	2	46
other	Middle Ear/Hearing	Ear and labyrinth disorders	Bevacizumab	2	46
other	Neutropenia	Blood and lymphatic system disorders	Bevacizumab	5	46
other	Thrombocytopenia	Blood and lymphatic system disorders	Bevacizumab	5	46
other	Lymphopenia	Blood and lymphatic system disorders	Bevacizumab	1	46
other	Leukopenia	Blood and lymphatic system disorders	Bevacizumab	10	46
other	Transfusion Prbc's	Blood and lymphatic system disorders	Bevacizumab	12	46
other	Anemia	Blood and lymphatic system disorders	Bevacizumab	33	46

1 to 10 of 150Source ClinicalTrials.gov

See all 150 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bevacizumab
Total, other adverse events	Bevacizumab	46	46
Total, serious adverse events	Bevacizumab	27	46

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA027469	Gynecologic Oncology Group	DISAIA, PHILIP J.	GYNECOLOGIC ONCOLOGY GROUP	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00025233

GET https://conductscience.org/api/trials/v1/NCT00025233/results?page=2

API reference For AI assistants